FLT3 and acute myeloid leukemia: Midostaurin was approved for treatment of FLT3-TKD/-ITDmut AML in the USA in 2017 and in the European Union in 2018 after the RATIFY trial proved that the addition of midostaurin to standard induction treatment significantly increased overall and event-free survival of patients with AML [15].